CliffBio
biologic

Beovu

brolucizumab-dbll

Loss of exclusivityOctober 2031projected — 12-year biologic exclusivity estimate
CompanyNovartis Pharmaceuticals Corporation

Drug detail

Brand nameBeovu
Active ingredientbrolucizumab-dbll
Strength6MG/0.05ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalOctober 2019
Marketing statusRx

More from Novartis Pharmaceuticals Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Beovu patent cliff — loss of exclusivity October 2031 | CliffBio